ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2011
Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 2 syntheses or guidelines pooled it, 190 citations in OpenAlex.
- Diabetes mellitus and prognosis in women with breast cancer: A systematic review and meta-analysis.Medicine · 2016Pooled it
- Does cancer risk increase with HbA1c, independent of diabetes?British journal of cancer · 2014Pooled it
- Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer.BMC cancer · 2022Trial
- Hemoglobin A1c Levels Modify Associations between Dietary Acid Load and Breast Cancer Recurrence.Nutrients · 2020Trial
- Recruitment strategies, design, and participant characteristics in a trial of weight-loss and metformin in breast cancer survivors.Contemporary clinical trials · 2016Trial
- Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance).Journal of oncology practice · 2014Trial
- Non-Fasting Glucose Measures and Their Clinical Significance in Diabetes Diagnosis and Cardiovascular and Cancer Risk Prediction: A Narrative Review.International journal of molecular sciences · 2026Review
- The association between pre-existing type 2 diabetes on cancer-related and all-cause mortality among women with breast cancer.Breast cancer research and treatment · 2026Article
- Exploring the potential effects of acute respiratory failure on patients with early-stage bronchopulmonary cancer.Scientific reports · 2025Article
- Impact of diabetes and glycemic control during cancer care on mortality in non-metastatic solid and hematologic malignancies.Annals of medicine · 2025Article
- Associations of low-density lipoprotein cholesterol and hemoglobin A1C with cardiovascular events and mortality in breast and prostate cancer patients.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Diabetes is causally associated with increased breast cancer mortality by inducing FIBCD1 to activate MCM5-mediated cell cycle arrest via modulating H3K27ac.Cell death & disease · 2025Article
- Insulin resistance and cancer: molecular links and clinical perspectives.Molecular and cellular biochemistry · 2025Review
- IGF1R activates FOXP3-β-catenin signaling to promote breast cancer development.Breast cancer research and treatment · 2025Article
- Health-related characteristics of Cancer survivors according to body mass index: a secondary data analysis.BMC cancer · 2025Article
- HbABMC cancer · 2025Article
- Pre-treatment nutrition-related indicators and the prognosis of patients with newly diagnosed epithelial ovarian cancer: an ambispective cohort study.Frontiers in nutrition · 2025Article
- Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical view.Journal of endocrinological investigation · 2024Review
- Impact of Breast Cancer on Cardiometabolic Health in Spanish Women ≥50 Years with Pre-Existing Type 2 Diabetes Mellitus.Cancers · 2024Article
- The combined treatment with ketogenic diet and metformin slows tumor growth in two mouse models of triple negative breast cancer.Translational medicine communications · 2024Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
purposeSelf-reported diabetes has been associated with poor breast cancer outcomes. Research is needed to investigate the relationship between biologically determined glycemic control and breast cancer prognosis.
methodsArchived baseline blood samples from the Women's Healthy Eating and Living Study were used to measure hemoglobin A1C (HbA1C) among 3,003 survivors of early-stage breast cancer (age of diagnosis, 28 to 70 years) observed for a median of 7.3 years for additional breast cancer events and 10.3 years for all-cause mortality. HbA1C levels provide an accurate, precise measure of chronic glycemic levels. Cox regression analysis was performed to assess whether baseline HbA1C levels predicted disease-free and overall survival.
resultsOnly 5.8% of women had chronic hyperglycemia (defined as HbA1C levels ≥ 6.5%). Those with HbA1C ≥ 6.5% were older and more likely to be less educated, have nonwhite ethnicity, be obese, and have more advanced breast cancer at diagnosis. HbA1C was significantly associated with overall survival (P(trend) < .001). After adjusting for confounders, risk of all-cause mortality was twice as high in women with HbA1C ≥ 7.0% compared with women with HbA1C less than 6.5% (hazard ratio [HR], 2.35; 95% CI, 1.56 to 3.54). For disease-free survival, there was a nonsignificant 30% increase in risk for HbA1C levels ≥ 7.0% (HR, 1.26; 95% CI, 0.78 to 2.02). During study follow-up, previously diagnosed rather than undiagnosed diabetes seemed to account for the increased risk.
conclusionChronic hyperglycemia is statistically significantly associated with reduced overall survival in survivors of early-stage breast cancer. Further study of diabetes and its relationship to breast cancer outcomes is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.